as Page 62 and 63: 64 europe Source: planet retail, as Page 64 and 65: 66 europe Source: planet retail, as Page 66 and 67: 68 europe Source: planet retail, as Page 68 and 69: 70 europe Sources: Corporate public Page 70 and 71: 72 europe Source: The Nielsen Compa Page 72 and 73: 74 europe Sources: MeTrO GrOup, eur Page 74 and 75: 76 europe Source: european Commissi Page 76 and 77: 78 consumer gooDs worlD traDe Sourc Page 78 and 79: 80 Source: Feri worlDwiDe economic Page 80 and 81: 82 Source: Feri worlDwiDe change in Page 82 and 83: 84 Source: planet retail, as of Jul Page 84 and 85: 86 Source: planet retail, as of Jul Page 86 and 87: 88 Source: planet retail, as of Jul Page 88 and 89: 90 Source: planet retail, as of Jul Page 90 and 91: 92 Source: planet retail, as of Jul Page 92 and 93: 94 Source: OC&C, FCMG Champions wor Page 94 and 95: 96 Sources: planetretail, MeTrO GrO Page 96 and 97: Buying power indices Itinerant reta Page 98 and 99: 100 1 plus 4 moDel a 1 plu Page 100 and 101: 102 assortment tomers and gauge lik Page 102 and 103: 104 auDiting auditing Also referred Page 104 and 105: 106 best practice principle sense o Page 106 and 107: 108 bsci Warenzeichen (tradem Page 108 and 109: 110 buyer structure Buyer Structure Page 110 and 111: 112 carD payment systems Card payme Page 112 and 113: 114 chain store company contrasts w Page 114 and 115: 116 concept leaDership company from Page 116 and 117: 118 consumer conFiDence 5

(2) Alzheimer's disease (progressive synapse and neuron loss)
and p.o
28 , 30113021.e3014 (2019)
Because Krystexxa is given intravenously, it would be expected that the great majority of its use would be by rheumatologists rather than by internists or primary care physicians
This is because the product primarily influences acetylcholine